Blueprint Medicines (NASDAQ:BPMC – Get Free Report) and Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Insider and Institutional Ownership 86.9% of Intra-Cellular […]
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) and Blueprint Medicines (NASDAQ:BPMC – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Analyst Ratings This is a summary of […]
Ipsen s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients .
Zai Lab (NASDAQ:ZLAB – Get Free Report) and Blueprint Medicines (NASDAQ:BPMC – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability. Institutional and Insider Ownership 54.0% of Zai […]